These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22005538)

  • 1. Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer.
    Cuffe S; Leighl NB
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1805-7. PubMed ID: 22005538
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
    Sun Z; Wang Z; Liu X; Wang D
    Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.
    Papadimitrakopoulou V
    J Thorac Oncol; 2012 Aug; 7(8):1315-26. PubMed ID: 22648207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidykinosital 3-kinase and mammalian target of rapamycin pathway in non-small-cell lung cancer.
    Massarelli E; Papadimitrakopoulou VA
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S379-82. PubMed ID: 23160325
    [No Abstract]   [Full Text] [Related]  

  • 6. Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling.
    Pal SK; Reckamp KL
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S487-9. PubMed ID: 21102251
    [No Abstract]   [Full Text] [Related]  

  • 7. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 8. The PI3K/AKT Pathway as a Target for Cancer Treatment.
    Mayer IA; Arteaga CL
    Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.
    Papadimitrakopoulou V; Adjei AA
    J Thorac Oncol; 2006 Sep; 1(7):749-51. PubMed ID: 17409953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of targeting mammalian target of rapamycin in lung cancer.
    Pal SK; Figlin RA; Reckamp KL
    Clin Lung Cancer; 2008 Nov; 9(6):340-5. PubMed ID: 19073516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target?
    Huang T; Lin X; Meng X; Lin M
    Acta Derm Venereol; 2014 Jul; 94(4):371-9. PubMed ID: 24217655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells.
    Li YC; He SM; He ZX; Li M; Yang Y; Pang JX; Zhang X; Chow K; Zhou Q; Duan W; Zhou ZW; Yang T; Huang GH; Liu A; Qiu JX; Liu JP; Zhou SF
    Cancer Lett; 2014 Mar; 344(2):239-59. PubMed ID: 24280585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC).
    Tan AC
    Thorac Cancer; 2020 Mar; 11(3):511-518. PubMed ID: 31989769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
    Bitting RL; Armstrong AJ
    Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mammalian target of rapamycin inhibitors for the targeted therapy of non-small cell lung cancer].
    Lin Y; Zhang L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr; 32(2):239-42. PubMed ID: 20450558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
    Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.